Advanced search
Publication Cover
Journal of Medical Economics Volume 20, 2017 - Issue 2
Submit an article Journal homepage
1,489
Views
11
CrossRef citations to date
0
Altmetric
Diabetes

Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy versus sulfonylurea monotherapy for people with type 2 diabetes and chronic kidney disease in Thailand

Unchalee PermsuwanFaculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand;
,
Piyameth DilokthornsakulCenter of Pharmaceutical Outcome Research (CPOR), Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand;
,
Kednapa ThavornOttawa Hospital Research Institute, The Ottawa Hospital, Ottawa, Ontario, Canada; ;School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada; ;Institute of Clinical and Evaluative Sciences, Toronto, Ontario, Canada;
,
Surasak SaokaewCenter of Health Outcomes Research and Therapeutic Safety (COHORTS), School of Pharmaceutical Sciences, University of Phayao, Phayao, Thailand; ;School of Pharmacy, Monash University Malaysia, Malaysia;
&
Nathorn ChaiyakunaprukCenter of Pharmaceutical Outcome Research (CPOR), Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand; ;School of Pharmacy, Monash University Malaysia, Malaysia; ;School of Population Health, University of Queensland, Brisbane, Australia; ;School of Pharmacy, University of Wisconsin-Madison, Wisconsin, MA, USACorrespondence[email protected] [email protected]
Pages 171-181 | Received 21 Jul 2016, Accepted 15 Sep 2016, Published online: 29 Sep 2016

Citations (11)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Zhen Ruan, Huimin Zou, Qing Lei, Carolina Oi Lam Ung, Honghao Shi & Hao Hu. (2022) Pharmacoeconomic evaluation of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus: a systematic literature review. Expert Review of Pharmacoeconomics & Outcomes Research 22:4, pages 555-574.
Read now

Articles from other publishers (10)

Soroush Ahmadi Fariman, Marzieh Nosrati, Parham Rahmani & Shekoufeh Nikfar. (2023) A cost-effectiveness analysis of linagliptin add-on to insulin treatment for patients with type 2 diabetes mellitus and chronic kidney disease in Iran. Journal of Diabetes & Metabolic Disorders 22:2, pages 1263-1271.
Crossref
Chaicharn Deerochanawong, Rungroj Krittayaphong, Jack Garcia Uranga Romano, Nicolai A. Rhee & Unchalee Permsuwan. (2023) Cost–Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand. Diabetes Therapy 14:3, pages 531-552.
Crossref
Saptarshi Bhattacharya & Sanjay Kalra. (2023) ADA–EASD Consensus Report on the Management of Hyperglycaemia in Type 2 Diabetes in an Afro-Asian Context: Broadening the Perspective. European Endocrinology 19:2, pages 1.
Crossref
Kah Yee Lum, Raymond Oppong & Jesse Kigozi. (2022) Economic Evaluation of Type 2 Diabetes Mellitus Interventions in Low- and Middle-Income Countries: A Systematic Review of the Literature. Asia Pacific Journal of Public Health 34:8, pages 752-760.
Crossref
Konkanok Wattana, Natnicha Poonchuay & Suriyon Uitrakul. (2022) Efficacy of vildagliptin on 10-year cardiovascular risk reduction in Thai patients with type 2 diabetes mellitus: A real-world observational study. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 16:3, pages 102437.
Crossref
Kriengsak Vareesangthip, Chaicharn Deerochanawong, Dittaya Thongsuk, Nuch Pojchaijongdee & Unchalee Permsuwan. (2022) Cost–Utility Analysis of Dapagliflozin as an Add-on to Standard of Care for Patients with Chronic Kidney Disease in Thailand. Advances in Therapy 39:3, pages 1279-1292.
Crossref
NIRUPAMA KULKARNI, MOPIDEVI RASI, NAZARIYA NIZAR, NISHOJA DAVID, PRASAD N BALI & VARSHA I DALAL. (2021) THE PHARMACOECONOMIC IMPACT OF GASTRO-PROTECTIVE AGENTS AT A TERTIARY CARE HOSPITAL. Asian Journal of Pharmaceutical and Clinical Research, pages 92-96.
Crossref
E. I. Rumiantseva & M. V. Avxentyeva. (2021) An economic evaluation of pre-dialysis stage of chronic kidney disease. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology 14:3, pages 365-378.
Crossref
Hai-Yen Nguyen-Thi, Nga TQ. Nguyen, Nguyen Dang Tu Le, Maud Beillat & Olivier Ethgen. (2020) Cost-Effectiveness of Gliclazide-Based Intensive Glucose Control vs. Standard Glucose Control in Type 2 Diabetes Mellitus. An Economic Analysis of the ADVANCE Trial in Vietnam. Frontiers in Public Health 8.
Crossref
Viswanathan Mohan, Kamlesh Khunti, Siew P. Chan, Fadlo F. Filho, Nam Q. Tran, Kaushik Ramaiya, Shashank Joshi, Ambrish Mithal, Maïmouna N. Mbaye, Nemencio A. NicodemusJr.Jr., Tint S. Latt, Linong Ji, Ibrahim N. Elebrashy & Jean C. Mbanya. (2019) Management of Type 2 Diabetes in Developing Countries: Balancing Optimal Glycaemic Control and Outcomes with Affordability and Accessibility to Treatment. Diabetes Therapy 11:1, pages 15-35.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.